KRAS and colorectal carcinoma: In addition, concomitant blockade of MEK and KRAS exhibits synergistic anti-tumor effect in KRAS-mutant CRC, which can provide a theoretical basis for the combination of MEK inhibitors and KRASG12C covalent inhibitors in treating KRASG12C-mutant CRC [112, 113].